Medical Policy and Coding Updates - October 2018
Effective October 1, 2018, CYP450 drug metabolizer genotyping codes 0028U, 0029U, 0031U, and 0070U through 0076U now require medical necessity review and prior authorization. Effective October 1, 2018, pegfilgrastim biosimilar Fulphila (Q5108) and filgrastim biosimilar Nivestym (Q5110) have medical necessity criteria added under the G-CSF policy, and custom ankle-foot and knee-ankle-foot orthoses (L1945, L2755) now require medical necessity review and prior authorization. MRgFUS ablation for movement disorder (0398T) now requires medical necessity review and prior authorization. Home enteral nutrition in-line digestive enzyme cartridges (Q9994), pain management opioid-use disorder genotyping (0078U), and sphenopalatine ganglion block (64505) are now reviewed as investigational. Drug testing with definitive confirmation (0020U) and knee orthosis L1847 no longer require medical necessity review, and L1847 no longer requires prior authorization, while supply code T5999 is now a non-covered service.